Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F F Rutten

Showing results (11-20 of 82) with videos related to

Pageof 9
Sort By:
Social Science & Medicine (1982)|January 1, 1983
Justice and health for allG A de Jong, F F Rutten
Health Services Research|January 1, 1977
Referrals and demand for specialist care in the NetherlandsF F Rutten, J van der Gaag
Nederlands Tijdschrift Voor Geneeskunde|January 1, 1994
[Costs of autologous bone marrow transplantation in non-Hodgkin lymphoma and acute leukemia]C A Uyl-de Groot, F F Rutten
Pharmacoeconomics|June 1, 2001
Cost effectiveness of continuous terbinafine compared with intermittent itraconazole in the treatment of dermatophyte toenail onychomycosis: an analysis of based on results from the L.I.ON. study. Lamisil versus Itraconazole in OnychomycosisR Jansen, W K Redekop, F F Rutten
Health Economics|November 14, 1997
Productivity costs in cost-effectiveness analysis: numerator or denominator: a further discussionW B Brouwer, M A Koopmanschap, F F Rutten
Pharmacoeconomics|July 6, 1996
The cost effectiveness of diclofenac plus misoprostol compared with diclofenac monotherapy in patients with rheumatoid arthritisM J Al, B C Michel, F F Rutten
International Journal of Technology Assessment in Health Care|October 22, 1998
Patient and informal caregiver time in cost-effectiveness analysis. A response to the recommendations of the Washington PanelW B Brouwer, M A Koopmanschap, F F Rutten
Nederlands Tijdschrift Voor Geneeskunde|November 5, 1994
[Costs of intensive care in The Netherlands]C N Hilgeman, M A Koopmanschap, F F Rutten
Social Science & Medicine (1982)|September 6, 2000
The evidence-based approach in health policy and health care deliveryL W Niessen, E W Grijseels, F F Rutten
Health Economics|May 1, 1997
Productivity costs measurement through quality of life? A response to the recommendation of the Washington PanelW B Brouwer, M A Koopmanschap, F F Rutten
Pageof 9

Showing results (11-20 of 82) with videos related to

Sort By:
Pageof 9
Social Science & Medicine (1982)|January 1, 1983
Justice and health for allG A de Jong, F F Rutten
Health Services Research|January 1, 1977
Referrals and demand for specialist care in the NetherlandsF F Rutten, J van der Gaag
Nederlands Tijdschrift Voor Geneeskunde|January 1, 1994
[Costs of autologous bone marrow transplantation in non-Hodgkin lymphoma and acute leukemia]C A Uyl-de Groot, F F Rutten
Pharmacoeconomics|June 1, 2001
Cost effectiveness of continuous terbinafine compared with intermittent itraconazole in the treatment of dermatophyte toenail onychomycosis: an analysis of based on results from the L.I.ON. study. Lamisil versus Itraconazole in OnychomycosisR Jansen, W K Redekop, F F Rutten
Health Economics|November 14, 1997
Productivity costs in cost-effectiveness analysis: numerator or denominator: a further discussionW B Brouwer, M A Koopmanschap, F F Rutten
Pharmacoeconomics|July 6, 1996
The cost effectiveness of diclofenac plus misoprostol compared with diclofenac monotherapy in patients with rheumatoid arthritisM J Al, B C Michel, F F Rutten
International Journal of Technology Assessment in Health Care|October 22, 1998
Patient and informal caregiver time in cost-effectiveness analysis. A response to the recommendations of the Washington PanelW B Brouwer, M A Koopmanschap, F F Rutten
Nederlands Tijdschrift Voor Geneeskunde|November 5, 1994
[Costs of intensive care in The Netherlands]C N Hilgeman, M A Koopmanschap, F F Rutten
Social Science & Medicine (1982)|September 6, 2000
The evidence-based approach in health policy and health care deliveryL W Niessen, E W Grijseels, F F Rutten
Health Economics|May 1, 1997
Productivity costs measurement through quality of life? A response to the recommendation of the Washington PanelW B Brouwer, M A Koopmanschap, F F Rutten
Pageof 9